Product Code: ANV2299
REPORT HIGHLIGHT
Recombinant Antibodies Market size was valued at USD 12,110 Million in 2023, expanding at a CAGR of 6.5% from 2024 to 2032.
Synthetic monoclonal antibodies, or recombinant antibodies, are created in vitro using recombinant DNA technology as a substitute for the traditional hybridoma-based approach of manufacturing monoclonal antibodies. Recombinant antibodies may be created without vaccinating animals since synthetic genes are employed to make them outside of the immune system. These synthetic antibodies are superior to traditional animal-derived antibodies in a number of respects and may be used in any application due to their high specificity, sensitivity, and repeatability.
Recombinant Antibodies Market- Market Dynamics
Increasing cases of cancer and infectious disease drives market growth
Over the projected period, the market for recombinant antibodies is anticipated to grow as a result of the rising incidence of infectious diseases and cancer cases worldwide. By identifying and attaching to antigens expressed on the surface of cancer cells, recombinant antibodies are engineered to precisely target cells that are cancerous. Compared to conventional chemotherapy, this focused approach reduces adverse effects and decreases harm to healthy cells. This may also be used to passive immunization, which offers instant defense against infectious pathogens. They can be given to those who are at danger or have been exposed to infections, such as in the event of certain viral epidemics, since they are made to resemble the immune response. For instance, according to estimates from the Global Cancer Observatory (GLOBOCAN), there will be 19.3 million incident cases of cancer globally in 2020. India placed third, behind the United States of America and China. 2.08 million new cases of cancer would be detected in India in 2040, up 57.5 percent from 2020.
Recombinant Antibodies Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.5% over the forecast period (2024-2032)
Based on type segmentation, the Single Chain Antibody segment is expected to capture the largest revenue share over the projected period
Based on application segmentation, the Pharmaceutical & Biotechnology segment is expected to dominate the market over the projected period
Based on region, North America is expected to dominate the market over the forecast period
Recombinant Antibodies Market- Segmentation Analysis:
The Global Recombinant Antibodies Market is segmented based on Type, Application and Region.
Based on the type, the Recombinant Antibodies market is bifurcated into Single Chain Antibody, Full Human Antibody, Humanized Antibody, Chimeric Antibody and Bispecific Antibody. The Single Chain Antibody segment is expected to capture the largest revenue share over the projected period. Recombinant DNA technology is used to manufacture single chain antibodies, enabling the modification of binding specificity and affinity. This characteristic increases their adaptability in focusing on particular antigens associated with a range of illnesses. Because of their smaller size and simpler structure than typical antibodies, scFv molecules are useful in some situations. greater tissue penetration may be made possible by their lower size, which might lead to greater therapeutic results.
Based on the application, the global Recombinant Antibodies market is segmented into Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology, Research Institutes and Others. The Pharmaceutical & Biotechnology segment is expected to dominate the market over the projected period. Major pharmaceutical and biotechnology companies invest heavily in research and development activities related to recombinant antibodies. Thus, driving the segment expansion.
Recombinant Antibodies Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. The regional market expansion is attributed to the presence of major players. Additionally, the rising prevalence of cancer and others infectious disease significantly drive the market growth in the region.
Recombinant Antibodies Market- Competitive Landscape:
The key players operating in the market are Bio-Rad Laboratories, GE Healthcare, F. Hoffmann-La Roche, BIOLEGEND, BD Biosciences, Creative Biolabs, Merck KGaA, Abnova, Abcam, SinoBiological, BBI Solutions, ProMab Biotechnologies and Beckman Coulter. These players adopted various strategies to gain major market share in the industry including product launch, acquisition, collaboration and others.
Recent Developments:
In November 2023, Lonza declared the opening of its new GS Effex(R) cell line to facilitate the production of more potent therapeutic antibodies. The GS Effex(R) cell line was created in response to urgent market demands brought on by the move toward more advanced therapeutic antibodies. GS Effex(R), which is derived from Lonza's top-performing GS Xceed(R) cell line, integrates well with Lonza platforms. When coupled with robust cell growth and the capacity to generate potent therapeutic antibodies, this unique cell line offers a solution for therapeutic development spanning from early-stage research to commercial manufacture.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RECOMBINANT ANTIBODIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Bio-Rad Laboratories
GE Healthcare
F. Hoffmann-La Roche
BIOLEGEND
BD Biosciences
Creative Biolabs
Merck KGaA
Abnova
Abcam
SinoBiological
BBI Solutions
ProMab Biotechnologies
Beckman Coulter
GLOBAL RECOMBINANT ANTIBODIES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032
- Single Chain Antibody
- Full Human Antibody
- Humanized Antibody
- Chimeric Antibody
- Bispecific Antibody
GLOBAL RECOMBINANT ANTIBODIES MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Hospitals & Diagnostic Laboratories
- Pharmaceutical & Biotechnology
- Research Institutes
- Others
GLOBAL RECOMBINANT ANTIBODIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1.Recombinant Antibodies Market Overview
- 1.1.Study Scope
- 1.2.Market Estimation Years
2.Executive Summary
- 2.1.Market Snippet
- 2.1.1.Recombinant Antibodies Market Snippet by Type
- 2.1.2.Recombinant Antibodies Market Snippet by Application
- 2.1.3.Recombinant Antibodies Market Snippet by Country
- 2.1.4.Recombinant Antibodies Market Snippet by Region
- 2.2.Competitive Insights
3.Recombinant Antibodies Key Market Trends
- 3.1.Recombinant Antibodies Market Drivers
- 3.1.1.Impact Analysis of Market Drivers
- 3.2.Recombinant Antibodies Market Restraints
- 3.2.1.Impact Analysis of Market Restraints
- 3.3.Recombinant Antibodies Market Opportunities
- 3.4.Recombinant Antibodies Market Future Trends
4.Recombinant Antibodies Industry Study
- 4.1.PEST Analysis
- 4.2.Porter's Five Forces Analysis
- 4.3.Growth Prospect Mapping
- 4.4.Regulatory Framework Analysis
5.Recombinant Antibodies Market: COVID-19 Impact Analysis
- 5.1.Pre-COVID-19 Impact Analysis
- 5.2.Post-COVID-19 Impact Analysis
- 5.2.1.Top Performing Segments
- 5.2.2.Marginal Growth Segments
- 5.2.3.Top Looser Segments
- 5.2.4.Marginal Loss Segments
6.Recombinant Antibodies Market Landscape
- 6.1.Recombinant Antibodies Market Share Analysis, 2023
- 6.2.Breakdown Data, by Key Manufacturer
- 6.2.1.Established Players' Analysis
- 6.2.2.Emerging Players' Analysis
7.Recombinant Antibodies Market - By Type
- 7.1.Overview
- 7.1.1.Segment Share Analysis, By Type, 2023 & 2032 (%)
- 7.1.2.Single Chain Antibody
- 7.1.3.Full Human Antibody
- 7.1.4.Humanized Antibody
- 7.1.5.Chimeric Antibody
- 7.1.6.Bispecific Antibody
8.Recombinant Antibodies Market - By Application
- 8.1.Overview
- 8.1.1.Segment Share Analysis, By Application, 2023 & 2032 (%)
- 8.1.2.Hospitals & Diagnostic Laboratories
- 8.1.3.Pharmaceutical & Biotechnology
- 8.1.4.Research Institutes
- 8.1.5.Others
9.Recombinant Antibodies Market- By Geography
- 9.1.Introduction
- 9.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
- 9.2.North America
- 9.2.1.Overview
- 9.2.2.Recombinant Antibodies Key Manufacturers in North America
- 9.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4.North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.2.5.North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.2.6.U.S.
- 9.2.6.1.Overview
- 9.2.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.6.3.U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.2.6.4.U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.2.7.Canada
- 9.2.7.1.Overview
- 9.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.2.7.3.Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.2.7.4.Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.Europe
- 9.3.1.Overview
- 9.3.2.Recombinant Antibodies Key Manufacturers in Europe
- 9.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4.Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.5.Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.6.Germany
- 9.3.6.1.Overview
- 9.3.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.6.3.Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.6.4.Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.7.Italy
- 9.3.7.1.Overview
- 9.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.7.3.Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.7.4.Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.8.United Kingdom
- 9.3.8.1.Overview
- 9.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.8.3.United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.8.4.United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.9.France
- 9.3.9.1.Overview
- 9.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.9.3.France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.9.4.France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.10.Russia
- 9.3.10.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.10.2.Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.10.3.Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.11.Netherlands
- 9.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.11.2.Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.11.3.Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.12.Sweden
- 9.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.12.2.Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.12.3.Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.13.Poland
- 9.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.13.2.Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.13.3.Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.14.Rest of Europe
- 9.3.14.1.Overview
- 9.3.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.3.14.3.Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.3.14.4.Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.Asia Pacific (APAC)
- 9.4.1.Overview
- 9.4.2.Recombinant Antibodies Key Manufacturers in Asia Pacific
- 9.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4.Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.5.Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.6.India
- 9.4.6.1.Overview
- 9.4.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.6.3.India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.6.4.India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.7.China
- 9.4.7.1.Overview
- 9.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.7.3.China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.7.4.China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.8.Japan
- 9.4.8.1.Overview
- 9.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.8.3.Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.8.4.Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.9.South Korea
- 9.4.9.1.Overview
- 9.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.9.3.South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.9.4.South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.10.Australia
- 9.4.10.1.Overview
- 9.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.10.3.Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.10.4.Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.11.Thailand
- 9.4.11.1.Overview
- 9.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.11.3.Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.11.4.Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.12.Indonesia
- 9.4.12.1.Overview
- 9.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.12.3.Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.12.4.Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.13.Philippines
- 9.4.13.1.Overview
- 9.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.13.3.Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.13.4.Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.14.Rest of APAC
- 9.4.14.1.Overview
- 9.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.4.14.3.Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.4.14.4.Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.Latin America
- 9.5.1.Overview
- 9.5.2.Recombinant Antibodies Key Manufacturers in Latin America
- 9.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4.Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.5.5.Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.6.Brazil
- 9.5.6.1.Overview
- 9.5.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.6.3.Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.5.6.4.Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.7.Mexico
- 9.5.7.1.Overview
- 9.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.7.3.Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.5.7.4.Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.8.Argentina
- 9.5.8.1.Overview
- 9.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.8.3.Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.5.8.4.Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.9.Colombia
- 9.5.9.1.Overview
- 9.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.9.3.Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.5.9.4.Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.10.Rest of LATAM
- 9.5.10.1.Overview
- 9.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.5.10.3.Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.5.10.4.Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.Middle East and Africa
- 9.6.1.Overview
- 9.6.2.Recombinant Antibodies Key Manufacturers in Middle East and Africa
- 9.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4.Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.6.5.Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.6.Saudi Arabia
- 9.6.6.1.Overview
- 9.6.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.6.3.Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.6.6.4.Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.7.United Arab Emirates
- 9.6.7.1.Overview
- 9.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.7.3.United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.6.7.4.United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.8.Israel
- 9.6.8.1.Overview
- 9.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.8.3.Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.6.8.4.Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.9.Turkey
- 9.6.9.1.Overview
- 9.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.9.3.Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.6.9.4.Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.10.Algeria
- 9.6.10.1.Overview
- 9.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.10.3.Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.6.10.4.Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.11.Egypt
- 9.6.11.1.Overview
- 9.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.11.3.Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.6.11.4.Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.12.Rest of MEA
- 9.6.12.1.Overview
- 9.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 9.6.12.3.Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 9.6.12.4.Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.Key Vendor Analysis- Recombinant Antibodies Industry
- 10.1.Competitive Dashboard
- 10.2.Company Profiles
- 10.2.1.Bio-Rad Laboratories
- 10.2.2.GE Healthcare
- 10.2.3.F. Hoffmann-La Roche
- 10.2.4.BIOLEGEND
- 10.2.5.BD Biosciences
- 10.2.6.Creative Biolabs
- 10.2.7.Merck KGaA
- 10.2.8.Abnova
- 10.2.9.Abcam
- 10.2.10.SinoBiological
- 10.2.11.BBI Solutions
- 10.2.12.ProMab Biotechnologies
- 10.2.13.Beckman Coulter
11.360 Degree Analyst View
12.Appendix
- 12.1.Research Methodology
- 12.2.References
- 12.3.Abbreviations
- 12.4.Disclaimer
- 12.5.Contact Us